コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 eous breathing (prevented by a neuromuscular blocking agent).
2 ded medications (aspirin and beta-adrenergic blocking agents).
3 id DCs that secrete the potent costimulation blocking agent.
4 hexamethonium (10 mg/kg, i.v.), a ganglionic blocking agent.
5 DS and had been treated with a neuromuscular blocking agent.
6 ses the impact of a cell cycle mitotic phase blocking agent.
7 d without injecting pharmacologic doses of a blocking agent.
8 d, or when using bovine serum albumin as the blocking agent.
9 FU/ml was achieved when 2% BSA was used as a blocking agent.
10 th myasthenia gravis receiving neuromuscular-blocking agents.
11 in a 1: 1 ratio with steroidal neuromuscular blocking agents.
12 lmonary fibroblasts were incubated with CTGF blocking agents.
13 ors are affected by the use of neuromuscular blocking agents.
14 ectively encapsulate steroidal neuromuscular blocking agents.
15 anslate these insights into prototypical DQ2 blocking agents.
16 ing different non-depolarizing neuromuscular blocking agents.
17 eiving continuous infusions of neuromuscular-blocking agents.
18 r nonresponders (n = 12) to therapy with TNF blocking agents.
19 may affect the outcome of treatment with TNF blocking agents.
20 nor the varying properties of different TNF-blocking agents.
21 xtracellular ion concentrations or potential blocking agents.
22 anding barriers to the effective use of beta-blocking agents.
23 , are relevant for the design of therapeutic blocking agents.
24 lity to block this passage with gap junction blocking agents.
25 channel in the context of ion permeation and blocking agents.
26 tubation in patients receiving neuromuscular-blocking agents.
27 ination with variable doses of neuromuscular blocking agents.
28 heart failure patients with beta-adrenergic blocking agents.
29 continuation of treatment with neuromuscular blocking agents.
30 ceiving continuous infusion of neuromuscular-blocking agents.
31 nt as demonstrated by studies with secretion blocking agents.
32 surgery or were treated with calcium channel blocking agents.
33 pha-2 adrenergic agonists or beta adrenergic blocking agents.
34 , shared to some extent with calcium channel blocking agents.
35 ing the treatment of heart failure with beta-blocking agents.
36 atients receiving infusions of neuromuscular-blocking agents.
37 g continuous administration of neuromuscular-blocking agents.
38 retion led to successful treatment with IL-1-blocking agents.
39 reaction, importantly, without the need for blocking agents.
40 who are increasingly treated with complement blocking agents.
41 ut beta-blockers or renin-angiotensin system blocking agents.
42 nts associated with the use of neuromuscular blocking agents.
43 respond dramatically to treatment with IL-1 blocking agents.
44 80 mg/dL in patients receiving neuromuscular-blocking agents.
45 , 2% BSA in 1.0 x 10-2 M, pH 7.4, PBS as the blocking agent, 0.5 mL/h as the sample flow rate, 1.0 x
49 BALB/c mice were given small molecule GRP blocking agent 77427, or GRP blocking antibody 2A11, bef
50 ng enzyme inhibitors or angiotensin receptor blocking agents 85.3% versus 77.4% (AOR, 1.62; 95% CI, 1
51 of xemilofiban, an oral platelet GP IIb/IIIa blocking agent, administered to patients after percutane
52 col should include guidance on neuromuscular-blocking agent administration in patients undergoing the
53 or the subset of patients on beta-adrenergic blocking agents after CABG, there was a trend toward les
54 Encouraging early clinical results using blocking agents against components of the PD-1 pathway h
55 s corticosteroids and neuromuscular junction-blocking agents, although the exposure to the latter dru
58 sociation between receipt of a neuromuscular blocking agent and in-hospital mortality among mechanica
59 alcium channel blockers if already on a beta-blocking agent and rate-limiting calcium channel blocker
61 (age 4 months), treated with a neuromuscular blocking agent and ventilated: control, hyperoxia-treate
62 dical treatments, including alpha-adrenergic blocking agents and 5 alpha-reductase inhibitors mean th
63 Without their use, dosing of neuromuscular blocking agents and anticholinesterases is often inappro
64 derivatives can be ablated by Ca(2+)-channel blocking agents and by the calcium chelator 1,2-bis(o-am
66 treatment with nondepolarizing neuromuscular blocking agents and corticosteroids in the intensive car
68 lth outcomes associated with beta-adrenergic blocking agents and diltiazem treatment for unstable ang
70 amined the association between neuromuscular blocking agents and ICU-acquired weakness, critical illn
72 s a modest association between neuromuscular blocking agents and neuromuscular dysfunction acquired i
73 ot show an association between neuromuscular blocking agents and neuromuscular dysfunction acquired i
75 lso associated with the use of neuromuscular blocking agents and prolonged mechanical ventilation, su
76 ous ELISA assay involves multiple steps with blocking agents and secondary reporters that ultimately
78 l the potential use of porins as targets for blocking agents and suggest that polyamines may act as e
79 is of the different orders of potency of the blocking agents and the differential response to 1-EBIO
80 been proposed based on the use of molecular blocking agents and transgenic animals to elucidate dise
81 7 years) who were not taking beta-adrenergic blocking agents and were referred for symptom-limited ex
82 operitoneal fibrosis include the use of beta-blocking agents, and connective tissue disease processes
84 acologic probes (lidocaine [a sodium channel blocking agent] and cesium [an outward potassium channel
86 Does nurse-led titration of beta-adrenergic blocking agents, angiotensin-converting enzyme inhibitor
88 capability when aspirin and beta-adrenergic blocking agents are given appropriately and transfer is
92 nd protocols could ensure that neuromuscular blocking agents are used and monitored appropriately.
95 data prompt the future development of an FSH-blocking agent as a means of uncoupling bone formation a
96 r patients with AMI, such as beta-adrenergic blocking agents, aspirin and immediate reperfusion thera
97 al variable found receipt of a neuromuscular blocking agent associated with a 4.3% (95% CI, -11.5%, 1
99 to a peripheral site of action of the nAChR-blocking agents at the neuromuscular junction (NMJ), bec
100 bility of four nondepolarizing neuromuscular blocking agents (atracurium, gallamine, metocurine, and
101 was to assess the effect of the inflammasome blocking agents BAY 11-7082 (30 mg/kg, i.p.) and Brillia
103 ests that a reduced dose of an neuromuscular-blocking agent be used for patients with myasthenia grav
105 linical practice suggests that neuromuscular-blocking agents be discontinued prior to the clinical de
107 tan, and intravenous injection of a ganglion blocking agent, but not an arginine vasopressin V1 recep
108 ated by hexamethonium, an autonomic ganglion blocking agent, but was abolished by CGRP-(8-37), an ant
110 of concomitant medications (beta-adrenergic blocking agents, calcium channel blocking agents or digo
111 A/1LacJ mice that were administered the CD80 blocking agents, called CD80-binding competitive antagon
112 nhibit DC maturation, whereas co-stimulation-blocking agents can also promote the induction of antige
113 luorescent dyes, the presence of these toxic blocking agents can be observed as a decrease in fluores
116 demonstrate that treatment with inflammasome-blocking agents can significantly reduce the development
117 +, Sr2+, Mg2+, and La3+) and by gap junction blocking agents (carbenoxolone, octanol, heptanol, flufe
118 studies with the alpha- and beta-adrenergic blocking agent carvedilol demonstrated a significant sur
120 he use of nondihydropyridine calcium channel blocking agents (CCBs) appears to reduce reinfarction in
121 tudy, we report the efficacy of a novel CD80-blocking agent CD80-competitive antagonist peptide (CD80
122 e the first evidence that a cyclooxygenase 2 blocking agent, celecoxib, possesses strong chemoprevent
123 ffects of the potent selective 5-HT reuptake blocking agent, citalopram (10 mg/kg, i.v.), on local ce
125 kness and included charges for neuromuscular blocking agents, continuous mechanical ventilation, ICU
126 perative administration of the costimulatory blocking agent CTLA4 immunoglobulin exhibited >100-day s
127 kg), together with the B7-CD28 costimulation blocking agent CTLA4Ig, 7 days before renal transplantat
128 Because most of the familiar Ca2+ channel blocking agents currently used in cardiology, such as ni
129 Dose-response studies with a translational blocking agent demonstrate that the cellular oxidative r
130 genation improved by beta-blockade and beta1-blocking agent did offset the adverse effect of epinephr
131 ce of female gender, greater calcium channel blocking agent, digoxin and diuretic use, lower heart ra
134 Thus, in addition to being an effective blocking agent during the initiation phase, these findin
136 ith nicotinic acetylcholine receptor (nAChR)-blocking agents [e.g., curare or alpha-bungarotoxin (alp
138 The short-acting beta1-selective adrenergic blocking agent, esmolol, was administrated during cardio
140 ed with that of the classical sodium channel blocking agent, flecainide, which has no recognized mono
143 lockade are relevant to the choice of a BAFF blocking agent for the treatment of autoimmune and malig
144 atients and have led to the approval of IL-1-blocking agents for a number of autoinflammatory conditi
146 endation on the routine use of neuromuscular-blocking agents for patients undergoing therapeutic hypo
147 l examples of pharmacologically suitable DQ2 blocking agents for the potential treatment of Celiac Sp
148 dings indicate the possible utility of IL-1R-blocking agents for the treatment of ocular inflammatory
149 l therapy with a diuretic or beta-adrenergic blocking agent, for which reductions in morbidity and mo
150 , including their sensitivity to replication-blocking agents, growth defects, and inefficient chromat
154 n the clinical pharmacology of neuromuscular blocking agents have advocated routine intraoperative us
157 ong-term safety of the tumor necrosis factor blocking agents have prompted investigators to take a cl
158 stage gametocytes and identify transmission-blocking agents have, until now, been hindered by a lack
159 e likely to receive aspirin, beta-adrenergic blocking agents, heparin and nitrates (all p < 0.0001).
161 intravenous administration of the ganglionic blocking agent hexamethonium (5 mg/kg) or an arginine va
162 and non-responses to tumour necrosis factor blocking agents, however, together with the increasing c
163 ent broth media was reported as an effective blocking agent; however, the natural background fluoresc
165 ne, along with potentiation by neuromuscular blocking agents, immobilization, and probably also concu
167 4-amino-pyridine (4-AP), a potassium channel-blocking agent, improves symptoms in some patients with
168 nd provides a rationale for the use of IL-22-blocking agents in B-cell-mediated autoimmune conditions
170 These data strongly support testing of PD-1-blocking agents in combination with standard-of-care che
171 such as aspirin, statins and beta-adrenergic blocking agents in conjunction with comprehensive lifest
172 3) We suggest a trial of a neuromuscular-blocking agents in life-threatening situations associate
174 tiated by ATP-sensitive K(+) (K-ATP) channel blocking agents in STN neurons but not in dopamine neuro
175 perior blocking efficacy compared with other blocking agents in terms of high signal-to-noise ratio w
180 This includes the injection of neuromuscular blocking agents into anterior scalene muscles to help co
181 ed in the prone position and a neuromuscular blocking agent is administered, without improvement in h
182 ection, early treatment with a neuromuscular blocking agent is associated with lower in-hospital mort
183 s patches (R(2) > 0.99), suggesting that the blocking agent is closely associated with the channel.
184 e hypothesized that the use of neuromuscular blocking agents is associated with a decreased prevalenc
186 kin's battery, by topical application of Na+ blocking agents leads to inhibition or disruption of nor
188 ls suggest that treatment with neuromuscular blocking agents may improve survival in patients requiri
189 -AW and provides evidence that neuromuscular blocking agents may not be a major cause of weakness in
190 studies have suggested that calcium channel-blocking agents may prevent new coronary lesion formatio
191 our data suggest that therapeutic CD40-CD40L blocking agents may prove efficacious not only in early
193 d mechanism for understanding how Na channel-blocking agents may suppress the pathologic, sustained N
194 suppress the sensitivity to the replication-blocking agent methylmethane sulfonate (MMS) in smc6 mut
195 ere reduced by the beta1-adrenergic receptor blocking agent metoprolol (1.5 mg/kg, intravenous), whic
196 to treatment with a beta-adrenergic-receptor blocking agent (metoprolol or carvedilol) or placebo.
197 some pairs of nondepolarizing neuromuscular blocking agents might be more efficacious because the hi
198 ective of chemical structural, neuromuscular blocking agents might produce prolonged paralysis in pre
199 toring and use of sedative and neuromuscular blocking agents, more mechanical ventilation days, and l
202 ing use of continuous-infusion neuromuscular blocking agents (NMB) in the intensive care unit (ICU).
203 4 (23%) lacked BSACI compliant neuromuscular blocking agent (NMBA) panels and 17/44 (39%) lacked a NA
204 Eleven patients received a neuromuscular blocking agent (NMBA) without a sedative/analgesic agent
210 use of sedatives, opioids, and neuromuscular blocking agents (NMBAs) may delay weaning and prolong in
213 Our results support the use of VEGF-C/VEGF-D-blocking agents not only to inhibit metastatic progressi
214 of sedative, analgesic, and/or neuromuscular blocking agents; nurse administration of these medicatio
217 ion with rAd encoding a potent costimulation blocking agent offers promise for therapy of allograft r
218 ry artery disease, nonuse of calcium channel blocking agents, older donor age, posttransplantation cy
220 to examine the effects of a beta-adrenergic blocking agent on the ischemic response to dobutamine st
221 of specific nonpeptide angiotensin receptor blocking agents on survival after myocardial infarction
225 ither timolol, a nonspecific beta adrenergic blocking agent, or with para-aminoclonidine, an alpha-2
226 y more likely to have received neuromuscular blocking agents (p = .004) or propofol (p =.026) for >1
227 s with first MI, patients on beta-adrenergic blocking agents, patients with LVEF < or =30%, patients
228 or vasopressors, sedatives, or neuromuscular blocking agents, percentage of patients that achieved un
230 An analysis using the hospital neuromuscular blocking agent-prescribing rate as an instrumental varia
234 re sedative, analgesic, and/or neuromuscular blocking agent, range 1-9 drugs, mean 2.5 (+1.5) drugs.
235 iving a continuous infusion of neuromuscular-blocking agent receive a structured physiotherapy regime
240 in immature female rats using estradiol as a blocking agent revealed specific uptake of [18F]FEDPN in
241 hypoxia exposure, and the use of a ganglion blocking agent should inhibit activity within all branch
242 0-year period, increasing evidence that beta-blocking agents should or actually did improve the natur
243 terference with the Tie-2 pathway by diverse blocking agents such as soluble Tie-2 receptors, anti-Ti
244 cluded from most trials of immune checkpoint blocking agents, such as anti-PD-1 and anti-PD-L1, becau
245 ghtly to several commonly used neuromuscular blocking agents, such as rocuronium, in aqueous solution
248 fines potential therapeutic target sites for blocking agents that could interfere with this interacti
251 centration, incubation times and the type of blocking agent to achieve a low limit of detection (LOD)
252 etermined the ability of a selectin receptor blocking agent to affect neutrophil deposition in tissue
255 c interventions in clinical disease by using blocking agents to ameliorate the systemic manifestation
256 c interventions in clinical disease by using blocking agents to ameliorate the systemic manifestation
257 e the capability to administer neuromuscular blocking agents to facilitate intubation (i.e., rapid se
258 e routine administration of an neuromuscular-blocking agents to mechanically ventilated patients with
259 examined the efficacy of two sodium channel blocking agents to protect white matter axons in two for
261 r treatment guidelines limit the use of HER2-blocking agents to tumors with HER2 gene amplification,
262 out of the sample zone and a small plug of "blocking agent" to negate the cells' mobility and induce
265 ients had significantly less beta-adrenergic blocking agent use and higher ejection fraction (EF) (p
266 performed to assess whether beta-adrenergic blocking agent use is associated with reduced mortality
267 analysis, the association of beta-adrenergic blocking agent use with reduced mortality remained signi
268 djusting for age, gender and beta-adrenergic blocking agent use, multiple logistic regression analysi
271 ded demographics, sedation and neuromuscular blocking agents used, mechanical ventilation, hemodynami
272 anaesthetized, injected with a neuromuscular blocking agent, vagotomized and artificially ventilated.
274 he effects of novel retinoic acid metabolism blocking agent, VN/14-1, in overcoming letrozole resista
275 ty for treatment, receipt of a neuromuscular blocking agent was associated with a reduced risk of in-
277 ion of the CRP system with several different blocking agents was also studied, and 2.0% bovine serum
280 erting enzyme inhibitors and calcium channel blocking agents was determined at discharge for all pati
281 eration in the presence of TNF-alpha or TNFR blocking agents was partially rescued by a TLR2 agonist,
283 ministration for sedatives and neuromuscular blocking agents were abstracted from ICU flow sheets.
285 erting-enzyme inhibitors and beta-adrenergic-blocking agents were administered if the patients could
289 ffects of various gene deletions or chemical blocking agents were tested by investigating the express
291 A short-acting beta1-selective adrenergic blocking agent, when administered during cardiopulmonary
294 nd another segment of solution containing a "blocking agent", which serves to stop the cell migration
296 gest that coformulation of this transmission-blocking agent with asexual stage antimalarials such as
298 ty of carvedilol, a "third-generation" beta -blocking agent with vasodilator properties, in chronic h
299 tion for clinical trials combining autophagy-blocking agents with antitumor drugs and radiation.
300 comes of patients treated with neuromuscular blocking agents within the first 2 hospital days to thos
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。